IL271788B1 - Compounds and methods for transmembrane transport of molecules - Google Patents

Compounds and methods for transmembrane transport of molecules

Info

Publication number
IL271788B1
IL271788B1 IL271788A IL27178819A IL271788B1 IL 271788 B1 IL271788 B1 IL 271788B1 IL 271788 A IL271788 A IL 271788A IL 27178819 A IL27178819 A IL 27178819A IL 271788 B1 IL271788 B1 IL 271788B1
Authority
IL
Israel
Prior art keywords
formula
set forth
group
solvates
hydrates
Prior art date
Application number
IL271788A
Other languages
English (en)
Hebrew (he)
Other versions
IL271788A (en
Inventor
Cohen Zedek Latzer Baratz Pearl
Original Assignee
Aposense Ltd
Cohen Zedek Latzer Baratz Pearl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/641,251 external-priority patent/US20190125884A1/en
Application filed by Aposense Ltd, Cohen Zedek Latzer Baratz Pearl filed Critical Aposense Ltd
Publication of IL271788A publication Critical patent/IL271788A/en
Publication of IL271788B1 publication Critical patent/IL271788B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
IL271788A 2017-07-04 2019-12-31 Compounds and methods for transmembrane transport of molecules IL271788B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15/641,251 US20190125884A1 (en) 2017-07-04 2017-07-04 Compounds and methods for trans-membrane delivery of molecules
US201715662665A 2017-07-28 2017-07-28
US201715679192A 2017-08-17 2017-08-17
US15/691,821 US10195286B2 (en) 2017-07-04 2017-08-31 Compounds and methods for trans-membrane delivery of molecules
PCT/IL2018/050714 WO2019008574A1 (en) 2017-07-04 2018-07-02 COMPOUNDS AND METHODS FOR TRANSMEMBRANE ADMINISTRATION OF MOLECULES

Publications (2)

Publication Number Publication Date
IL271788A IL271788A (en) 2020-02-27
IL271788B1 true IL271788B1 (en) 2026-01-01

Family

ID=64903980

Family Applications (1)

Application Number Title Priority Date Filing Date
IL271788A IL271788B1 (en) 2017-07-04 2019-12-31 Compounds and methods for transmembrane transport of molecules

Country Status (8)

Country Link
US (1) US10195286B2 (https=)
EP (1) EP3648773A4 (https=)
JP (1) JP7191869B2 (https=)
CN (1) CN111246855A (https=)
AU (1) AU2018295899B2 (https=)
CA (1) CA3068165A1 (https=)
IL (1) IL271788B1 (https=)
WO (1) WO2019008574A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267919B2 (en) 2017-01-09 2024-03-01 Aposense Ltd Compounds and methods for transmembrane transfer of molecules
US11236334B2 (en) 2017-08-22 2022-02-01 National University Corporation Nagoya University Modified polynucleotide
IL275773B2 (en) * 2018-01-01 2025-07-01 Aposense Ltd Compounds and methods for trans-membrane delivery of molecules
WO2020044349A1 (en) * 2018-08-30 2020-03-05 Aposense Ltd. Compounds, cojugates and compositions for use in the methods for trans-membrane delivery of molecules
US12606863B2 (en) 2021-05-13 2026-04-21 Promega Corporation Bioluminescent detection of DNA synthesis
JPWO2023022055A1 (https=) * 2021-08-17 2023-02-23

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017029664A1 (en) * 2015-08-20 2017-02-23 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
WO2018127927A1 (en) * 2017-01-09 2018-07-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1622572B1 (en) 2003-04-30 2017-12-20 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
WO2012018729A1 (en) 2010-08-03 2012-02-09 Berry And Associates, Inc. Phosphoramidite derivatives of folic acid
CA2944141C (en) 2014-03-28 2023-03-28 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017029664A1 (en) * 2015-08-20 2017-02-23 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
WO2018127927A1 (en) * 2017-01-09 2018-07-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules

Also Published As

Publication number Publication date
EP3648773A4 (en) 2021-06-09
AU2018295899A1 (en) 2020-02-20
US10195286B2 (en) 2019-02-05
JP7191869B2 (ja) 2022-12-19
WO2019008574A1 (en) 2019-01-10
AU2018295899B2 (en) 2024-03-21
JP2020525502A (ja) 2020-08-27
EP3648773A1 (en) 2020-05-13
CA3068165A1 (en) 2019-01-10
US20190008976A1 (en) 2019-01-10
IL271788A (en) 2020-02-27
CN111246855A (zh) 2020-06-05

Similar Documents

Publication Publication Date Title
IL271788B1 (en) Compounds and methods for transmembrane transport of molecules
JP6669719B2 (ja) 分子の膜貫通送達のための化合物および方法
US5578718A (en) Thiol-derivatized nucleosides
AU2018205898B2 (en) Compounds and methods for trans-membrane delivery of molecules
JP2018523680A (ja) 分子の膜貫通送達のための化合物及び方法
WO2024140101A1 (zh) 修饰的双链寡核苷酸分子、修饰的双链寡核苷酸缀合物及其用途
JP2024026212A (ja) 分子の膜貫通送達のための化合物および方法
US20190125884A1 (en) Compounds and methods for trans-membrane delivery of molecules
US20220112493A1 (en) Phosphonoacetate gapmer oligonucleotides
HK40027749A (en) Compounds and methods for trans-membrane delivery of molecules
WO2020044349A1 (en) Compounds, cojugates and compositions for use in the methods for trans-membrane delivery of molecules
AU2024351425C1 (en) Mrna cap analog and use thereof
JPH0856679A (ja) Ｒｎａ切断性又はｒｎａ結合性オリゴヌクレオチド
KR20210132681A (ko) 신규 포스포라미디트
HK40034155A (en) Compounds and methods for trans-membrane delivery of molecules